Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate
about
Therapeutic implications of autoantibodies in rheumatoid arthritisReceptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis.Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Cigarette Smoke Induces Immune Responses to Vimentin in both, Arthritis-Susceptible and -Resistant Humanized Mice.Osteoimmunology: from mice to humansAnti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis.The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.Synovial tissue research: a state-of-the-art review.How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins.STAT4 rs7574865 G/T polymorphism is associated with rheumatoid arthritis and disease activity, but not with anti-CCP antibody levels in a Mexican population.An increased concentration of receptor activator of nuclear factor kappa-B ligand pre-dates the onset of rheumatoid arthritis.Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients.Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.Periodontal disease influences osteoclastogenic bone markers in subjects with and without rheumatoid arthritis.The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
P2860
Q26744033-FDA3ADBF-618B-4FF0-A838-24D81E979DCBQ33592037-83B8072A-AA12-4558-841A-7B9E439A824EQ34545263-0184AD4D-3541-4544-98B2-30DECC63098FQ36125082-46BD6F59-D608-431C-84BF-051E949B0C2AQ36911794-4E9FF57A-9EAC-40E0-9AC1-0A353C52FA0CQ37315396-0F699E6C-2F6F-43D8-813A-108FAFA9DA5AQ38631840-FA6B7A59-C491-42F4-BBF0-82A8327B624AQ38831693-4B8E5276-4C97-424F-BAF9-9914F8CA3A77Q39431367-4E7D6128-B049-4546-8B19-3580BCC225F7Q39812962-231CB700-7C20-4A60-A680-8A1E2A3C1B88Q40731802-5E873D55-EDFB-4CFA-93C3-FC2C6C0F3E78Q47175280-47F67B15-0036-4EEE-854C-5EC448180882Q51117846-2391BA13-F7A0-4AD9-BA6D-8AC90E478C00Q54014686-2C6EA5D6-5CEF-4BE0-8EAA-683EEB1E9046Q55265895-29A9FD4F-2895-4392-AA56-87B5D487D874Q55689191-81EC70D2-3AC5-42AD-9182-C12279B86D6F
P2860
Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Serum RANKL levels associate w ...... dulated following methotrexate
@ast
Serum RANKL levels associate w ...... dulated following methotrexate
@en
type
label
Serum RANKL levels associate w ...... dulated following methotrexate
@ast
Serum RANKL levels associate w ...... dulated following methotrexate
@en
prefLabel
Serum RANKL levels associate w ...... dulated following methotrexate
@ast
Serum RANKL levels associate w ...... dulated following methotrexate
@en
P2093
P2860
P50
P1476
Serum RANKL levels associate w ...... dulated following methotrexate
@en
P2093
Aase Haj Hensvold
Anca Irinel Catrina
Ferhan Qureshi
Karin Lundberg
Lena Israelsson
Michaela Larkin
Nadine Defranoux
Wanying Li
P2860
P2888
P356
10.1186/S13075-015-0760-9
P577
2015-09-04T00:00:00Z
P5875
P6179
1018889589